Lilly’s Mounjaro in Short Supply Again as Demand Surges (1)

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro, which is commonly used off-label for weight loss, is again in short supply due to increased demand.

There will be limited availability of higher doses of the treatment through early March, according to a US Food and Drug Administration database that tracks shortages. So far, the FDA doesn’t list Mounjaro’s sister drug Zepbound, which is approved for weight loss, on its shortage list, though the two contain the same active ingredient.

The company is continuing to ship all doses to wholesalers, but anticipates intermittent backorders of higher doses over the next ...